View:
LION BIOTECHNOLOGIES, INC.
21900 BURBANK BLVD. THIRD FLOOR
WOODLAND HILLS, CA 91367
January 29, 2014
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-6010
|
Re:
|
Lion Biotechnologies, Inc.; Registration Statement on Form S-1
(Reg. No. 333-192649)
|
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned hereby requests acceleration of the effective date of the above-referenced Registration Statement to 4:00 P.M., Washington, D.C. time, on Thursday, January 30, 2014, or as soon thereafter as is practicable. Please call Istvan Benko at (310) 789-1226 to confirm the effectiveness.
In making this request, Lion Biotechnologies, Inc. (“Lion Biotechnologies”) acknowledges that:
|
|
·
|
should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, that act will not foreclose the Commission from taking any action with respect to the filing;
|
|
|
·
|
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective does not relieve Lion Biotechnologies from its full responsibility for the adequacy and accuracy of the disclosures in the Registration Statement; and
|
|
|
·
|
Lion Biotechnologies may not assert staff comments or the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
|
Lion Biotechnologies also understands that this request for acceleration will be considered a confirmation of its awareness of its obligations under the Securities Act of 1933 and the Securities Exchange Act of 1934 with respect to the offering of securities pursuant to the Registration Statement.
Very truly yours,
/s/ Michael Handelman
Michael Handelman
Chief Financial Officer
cc: Istvan Benko